



# Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial

Correction to: *Nature Communications*  
<https://doi.org/10.1038/s41467-023-42744-y>,  
published online 02 November 2023

<https://doi.org/10.1038/s41467-023-44071-8>

Published online: 12 December 2023

Check for updates

Laurence Buisseret , Delphine Loirat, Philippe Aftimos, Christian Maurer , Kevin Punie , Véronique Debien, Paulus Kristanto , Daniel Eiger, Anthony Goncalves, François Ghiringhelli , Donatienne Taylor , Florent Clatot, Tom Van den Mooter, Jean-Marc Ferrero, Hervé Bonnefoi, Jean-Luc Canon, Francois P. Duhoux , Laura Mansi, Renaud Poncin, Philippe Barthélémy, Nicolas Isambert, Zoë Denis, Xavier Catteau, Roberto Salgado , Elisa Agostinetti , Evandro de Azambuja, Françoise Rothé, Ligia Craciun, David Venet, Emanuela Romano , John Stagg , Marianne Paesmans, Denis Larsimont, Christos Sotiriou , Michail Ignatiadis & Martine Piccart-Gebhart

In the “Discussion” section of the original manuscript, the authors reported information and data related to an unpublished work (*Metoikidou C. and colleagues*). Considering the confidential nature of these data, it has been decided to remove the related paragraph from the “Discussion” section. The original text has been replaced with the following statement:

*“In an ongoing analysis by single-cell RNA sequencing on tumors from a subset of patients from the SYNERGY trial, Metoikidou C. and colleagues observed distinct transcriptomic and TCR-clonal patterns in responders vs. non-responder patients and between treatment arms (personal communication). These analyses will shed light on the immune parameters associated with outcome to chemo-immunotherapy.”*

These changes have been implemented in the PDF and HTML versions of the Article.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023